SCHEMBL5859893

SCHEMBL5859893

COC(=O)[C@H](Cc1ccc(CC(=O)N(C)C)cc1)NC(=O)C12CC3CC(C1)CC(C(=O)OC)(C3)C2

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.60
NPSR1 Q6W5P4 2/20 0.60
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 2/20 0.42
MAPT P10636 2/20 0.41
CYP2D6 P10635 1/20 0.41
ITGB1 P05556 1/20 0.41
ITGA4 P13612 1/20 0.41
TSHR P16473 3/20 0.39
ABL1 P00519 1/20 0.39
RIN1 Q13671 1/20 0.39
KLKB1 P03952 1/20 0.38
CYP3A4 P08684 2/20 0.38
EPHX2 P34913 1/20 0.38
ATM Q13315 2/20 0.37
LMNA P02545 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5860898 0.92 KMT2A (0.49) KMT2ANPSR1MEN1MAPTCYP2D6
SCHEMBL5859761 0.89 KMT2A (0.63) KMT2ANPSR1ALDH1A1MEN1MAPT
SCHEMBL6150797 0.87 NPSR1 (0.59) KMT2ANPSR1ALDH1A1MEN1MAPT
SCHEMBL5859997 0.86 KMT2A (0.64) KMT2ANPSR1ALDH1A1MEN1MAPT
SCHEMBL5859846 0.84 KMT2A (0.55) KMT2ANPSR1ALDH1A1MEN1MAPT
SCHEMBL5859967 0.84 KMT2A (0.55) KMT2ANPSR1ALDH1A1MAPTCYP2D6
SCHEMBL5859748 0.83 KMT2A (0.61) KMT2ANPSR1ALDH1A1MEN1MAPT
SCHEMBL5859743 0.83 KMT2A (0.51) KMT2ANPSR1ALDH1A1MEN1MAPT
SCHEMBL5862624 0.81 KMT2A (0.58) KMT2ANPSR1ITGB1ITGA4
SCHEMBL5862666 0.80 KMT2A (0.49) KMT2ANPSR1ALDH1A1MAPTCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115768-B2 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 ELAN PHARMACEUTICALS, INC. (US) 2006-10-03 US disclosed
US-20060074110-A1 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 ELAN PHARMACEUTICALS, INC. 2006-04-06 US disclosed
EP-1144364-B1 MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARM INC (US) 2005-07-13 EP disclosed
US-20030134874-A1 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 GRANT FRANCINE S (US) 2003-07-17 US disclosed
US-6465513-B1 SUCH AS N-(ADAMANT-1-YLCARBONYL)-L-4-(N,N-DIMETHYLCARBAMYL-OXY)PHENYLALANINE; INFLAMMATORY DISEASES SUCH AS ASTHMA, AIDS DEMENTIA, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, DIABETES, INFLAMMATORY BOWEL DISEASE, RHEUMATOID ARTHRITIS ELAN PHARMACEUTICALS, INC. 2002-10-15 US disclosed
EP-1144364-A2 MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 Elan Pharmaceuticals, Inc. (US) 2001-10-17 EP disclosed
WO-2000043354-A2 MULTICYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134874-A1 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 VCAM1, ICAM1, CD4 KMT2A 1620/4885NPSR1 1381/4885ALDH1A1 258/4885
US-20060074110-A1 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 VCAM1, ICAM1, CD4 KMT2A 1620/4885NPSR1 1381/4885ALDH1A1 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.